hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06336395, orgStudyIdInfo id: 2019/00888, briefTitle: Ma-Spore ALL 2020 Study, statusModule overallStatus: RECRUITING, startDateStruct date: 2020-03-04, primaryCompletionDateStruct date: 2030-03, completionDateStruct date: 2030-03, studyFirstPostDateStruct date: 2024-03-28, lastUpdatePostDateStruct date: 2024-03-28, sponsorCollaboratorsModule leadSponsor name: National University Hospital, Singapore, class: OTHER, descriptionModule briefSummary: The primary objective of this trial is to improve the overall survival rate of children and young adult with B-lineage acute lymphoblastic leukemia (B-ALL) in Singapore and Malaysia in the context of a multicenter cooperative trial using a risk-stratified therapy., conditionsModule conditions: B Lymphoblastic Leukemia, designModule studyType: INTERVENTIONAL, phases: PHASE2, designInfo allocation: NON_RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 500, type: ESTIMATED, armsInterventionsModule interventions name: Prednisolone, interventions name: Dexamethasone, interventions name: Vincristine, interventions name: Methotrexate, interventions name: L-Asparaginase, interventions name: Pegylated asparaginase, interventions name: Erwinase, interventions name: Dasatinib, interventions name: Imatinib, interventions name: Cyclophosphamide, interventions name: Cytarabine, interventions name: Mercaptopurine, interventions name: Thioguanine, interventions name: Rituximab, interventions name: Doxorubicin, interventions name: Fludarabine, outcomesModule primaryOutcomes measure: Overall survival (OS), secondaryOutcomes measure: Event free survival (EFS), otherOutcomes measure: Cumulative incidence (CI) of relapse for all treated cohorts, otherOutcomes measure: Cumulative incidence (CI) of therapy-related mortality (TRM) for all treated subjects, eligibilityModule sex: ALL, maximumAge: 40 Years, stdAges: CHILD, stdAges: ADULT, contactsLocationsModule locations facility: Subang Jaya Medical Centre, status: RECRUITING, city: Kuala Lumpur, zip: 47500, country: Malaysia, contacts name: Hai Peng Lin, role: CONTACT, phone: +603 56391621, email: flslhp@gmail.com, contacts name: Lee Lee Chan, MBBS, role: SUB_INVESTIGATOR, geoPoint lat: 3.1412, lon: 101.68653, locations facility: University Malaya Medical Centre, status: RECRUITING, city: Kuala Lumpur, zip: 59100, country: Malaysia, contacts name: Hany Arrifin, MBBS, role: CONTACT, phone: +603 79492065, email: hany@ummc.edu.my, geoPoint lat: 3.1412, lon: 101.68653, locations facility: KK Women's and Children's Hospital, status: RECRUITING, city: Singapore, zip: 229899, country: Singapore, contacts name: Ah Moy Tan, MBBS, role: CONTACT, phone: +65 63941039, email: tan.ah.moy01@singhealth.com.sg, geoPoint lat: 1.28967, lon: 103.85007, hasResults: False
protocolSection identificationModule nctId: NCT06336382, orgStudyIdInfo id: 23-0874, secondaryIdInfos id: 1R21MH135148, type: NIH, link: https://reporter.nih.gov/quickSearch/1R21MH135148, briefTitle: Tau Biomarkers in Late-onset Psychosis (LOP), statusModule overallStatus: RECRUITING, startDateStruct date: 2024-02-16, primaryCompletionDateStruct date: 2026-12-31, completionDateStruct date: 2027-06-30, studyFirstPostDateStruct date: 2024-03-28, lastUpdatePostDateStruct date: 2024-03-28, sponsorCollaboratorsModule leadSponsor name: Jeremy Koppel, class: OTHER, collaborators name: National Institute of Mental Health (NIMH), descriptionModule briefSummary: Hallucinations or delusions that occur for the first time in older people with no acute medical problems or mood symptoms may be related to impending dementia. This study aims to confirm this hypothesis using novel blood biomarkers and Positron Emission Tomography (PET) imaging tracers, as well as non-invasive testing., conditionsModule conditions: Late Onset Schizophrenia, conditions: Delusional Disorder (Late Onset), designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 16, type: ESTIMATED, armsInterventionsModule interventions name: Tau PET imaging scan, outcomesModule primaryOutcomes measure: Quantification of neurofibrillary tangle pathology in subjects via PET [18F]PI-2620 radiotracer uptake., secondaryOutcomes measure: Measurement of peripheral soluble tau pathology with tau plasma immunoassays., otherOutcomes measure: Evaluation of sensorimotor gating integrity and it's association to tau PET ligand uptake., eligibilityModule sex: ALL, minimumAge: 65 Years, maximumAge: 85 Years, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: The Feinstein Institutes for Medical Research, status: RECRUITING, city: Manhasset, state: New York, zip: 11030, country: United States, contacts name: Erica Christen, MS, role: CONTACT, phone: 516-562-3492, email: EChriste@northwell.edu, contacts name: Michelle Gong, AS, role: CONTACT, phone: 516-562-3492, email: MGong@northwell.edu, geoPoint lat: 40.79788, lon: -73.69957, hasResults: False
protocolSection identificationModule nctId: NCT06336369, orgStudyIdInfo id: 1713/2023, briefTitle: Brown Adipose Tissue Activity in Gilbert's Syndrome, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-03-06, primaryCompletionDateStruct date: 2027-01-15, completionDateStruct date: 2027-01-15, studyFirstPostDateStruct date: 2024-03-28, lastUpdatePostDateStruct date: 2024-03-28, sponsorCollaboratorsModule leadSponsor name: Medical University of Vienna, class: OTHER, collaborators name: University of Vienna, collaborators name: Griffith University, descriptionModule briefSummary: The goal of this case-control study is to investigate energy metabolism and brown adipose tissue (BAT) activity in individuals with Gilbert's syndrome (GS) and controls. The main focus of the study is to analyze:1. the link between bilirubin metabolism and metabolic health.2. energy metabolism and body composition in individuals with Gilbert's syndrome and control subjects3. brown adipose tissue activity in Gilbert's syndrome and healthy controls.Participants will undergo the following investigations:1. cold exposure2. PET-CT imaging with 18-F-FDG3. MRI imaging of liver, abdominal fat and muscle4. blood sampling5. indirect calorimetry6. bioelectrical impedance analysis7. infrared thermographyResearchers will compare individuals with GS and control subjects in terms of metabolic health, body composition and BAT activity., conditionsModule conditions: Gilbert Syndrome, designModule studyType: OBSERVATIONAL, designInfo observationalModel: CASE_CONTROL, timePerspective: PROSPECTIVE, enrollmentInfo count: 80, type: ESTIMATED, armsInterventionsModule interventions name: analyzing brown adipose tissue, body composition and metabolic health, outcomesModule primaryOutcomes measure: cold-induced brown adipose tissue (BAT) activation, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 65 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Medical University of Vienna, status: RECRUITING, city: Vienna, zip: 1090, country: Austria, contacts name: Florian Kiefer, MD, PhD, role: CONTACT, phone: +43140400, phoneExt: 43120, email: florian.kiefer@meduniwien.ac.at, geoPoint lat: 48.20849, lon: 16.37208, hasResults: False
protocolSection identificationModule nctId: NCT06336356, orgStudyIdInfo id: D6970C00011, briefTitle: A Study to Evaluate Cortisol Reserve in Response to Adrenocorticotropic Hormone (ACTH) Stimulation Test Following Baxdrostat Treatment Compared to Placebo in Participants With Uncontrolled Hypertension, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05-13, primaryCompletionDateStruct date: 2024-11-05, completionDateStruct date: 2024-11-05, studyFirstPostDateStruct date: 2024-03-28, lastUpdatePostDateStruct date: 2024-03-28, sponsorCollaboratorsModule leadSponsor name: AstraZeneca, class: INDUSTRY, descriptionModule briefSummary: The main purpose of this study is to assess the serum free cortisol response after ACTH stimulation test at baseline and at Week 8 in participants with uncontrolled hypertension., conditionsModule conditions: Uncontrolled Hypertension, designModule studyType: INTERVENTIONAL, phases: PHASE2, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: DOUBLE, whoMasked: PARTICIPANT, whoMasked: INVESTIGATOR, enrollmentInfo count: 45, type: ESTIMATED, armsInterventionsModule interventions name: Baxdrostat, interventions name: Placebo, outcomesModule primaryOutcomes measure: Individual Cortisol Level, secondaryOutcomes measure: Number of Participants with Abnormal Stimulated Cortisol, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06336343, orgStudyIdInfo id: STUDY-23-01698, briefTitle: Bimekizumab in Plaque Psoriasis, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-03, primaryCompletionDateStruct date: 2025-10-31, completionDateStruct date: 2025-10-31, studyFirstPostDateStruct date: 2024-03-28, lastUpdatePostDateStruct date: 2024-03-28, sponsorCollaboratorsModule leadSponsor name: Icahn School of Medicine at Mount Sinai, class: OTHER, collaborators name: UCB Pharma, collaborators name: Psoriasis Treatment Center of Central New Jersey, descriptionModule briefSummary: The purpose of this research study is to evaluate the effectiveness and safety of bimekizumab in individuals with moderate-to-severe psoriasis who have failed similar therapies. Bimekizumab improves psoriasis by suppressing a type of substance found in bodies called interleukins (specifically, interleukins 17a and 17F), which are known to increase inflammation. This study will look at the effectiveness of bimekizumab in psoriasis patients that have failed previous therapies that target interleukin IL-17A or 23., conditionsModule conditions: Plaque Psoriasis, designModule studyType: INTERVENTIONAL, phases: PHASE4, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 60, type: ESTIMATED, armsInterventionsModule interventions name: Bimekizumab, outcomesModule primaryOutcomes measure: Body Surface Area (BSA) of < 1, secondaryOutcomes measure: Psoriasis and Severity Index Score (PASI) of < 1, secondaryOutcomes measure: Physician Global Assessment (PGA) of < 1, secondaryOutcomes measure: Psoriasis and Severity Index Score (PASI) of < 2, secondaryOutcomes measure: Physician Global Assessment (PGA) of < 2, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Windsor Dermatology - Psoriasis Treatment Center of Central New Jersey, status: RECRUITING, city: East Windsor, state: New Jersey, zip: 08520, country: United States, contacts name: Elise Nelson, role: CONTACT, phone: 609-443-4500, contacts name: Jerry Bagel, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 40.268, lon: -74.54043, locations facility: Icahn School of Medicine at Mount Sinai, status: RECRUITING, city: New York, state: New York, zip: 10029, country: United States, contacts name: Giselle Singer, role: CONTACT, phone: 212-241-3288, contacts name: Mark Lebwohl, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 40.71427, lon: -74.00597, hasResults: False
protocolSection identificationModule nctId: NCT06336317, orgStudyIdInfo id: ELIMINATE-2024, briefTitle: Effect of infLuenza vaccInation After Myocardial INfArction on Cardiac inflammaTory responsE, acronym: ELIMINATE, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04, primaryCompletionDateStruct date: 2027-12, completionDateStruct date: 2027-12, studyFirstPostDateStruct date: 2024-03-28, lastUpdatePostDateStruct date: 2024-03-28, sponsorCollaboratorsModule leadSponsor name: Region Örebro County, class: OTHER, collaborators name: The Swedish Heart and Lung Association, collaborators name: Örebro University, Sweden, collaborators name: University of Cambridge, descriptionModule briefSummary: The goal of this randomized, double-blind, placebo-controlled clinical trial is to investigate the immunological effects of influenza vaccination outside of the influenza season on arterial inflammation in patients with a recent acute myocardial infarction (AMI). The primary objective is to compare the effects of influenza vaccination to those of a placebo in reducing post-myocardial infarction coronary inflammation as measured by coronary computed tomography angiography (CCTA). The main questions it aims to answer are:Does influenza vaccination reduce arterial inflammation as measured by CCTA at week 8 after percutaneous coronary intervention (PCI) in comparison to baseline? Does influenza vaccination modulate systemic inflammation as measured by blood biomarkers and in-vitro challenge tests at week 8 after PCI in comparison to baseline? Researchers will compare the effects of influenza vaccination with those of a placebo., conditionsModule conditions: Acute Myocardial Infarction, conditions: Cardiovascular Diseases, conditions: Inflammatory Response, designModule studyType: INTERVENTIONAL, phases: PHASE4, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: QUADRUPLE, whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, whoMasked: INVESTIGATOR, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 90, type: ESTIMATED, armsInterventionsModule interventions name: Influenza vaccine, interventions name: Placebo, outcomesModule primaryOutcomes measure: The right coronary artery, secondaryOutcomes measure: The whole coronary tree, secondaryOutcomes measure: Ascending aorta, secondaryOutcomes measure: Interleukin 1 beta (IL-1β), secondaryOutcomes measure: Tumor necrosis factor alpha (TNF-α), secondaryOutcomes measure: Interleukin-2 receptor (IL-2r), secondaryOutcomes measure: Interleukin Interleukin-6 (IL-6 ), secondaryOutcomes measure: Ferritin, secondaryOutcomes measure: Troponin-I, secondaryOutcomes measure: N-terminal pro-B-type natriuretic peptide, otherOutcomes measure: Explorative endpoints, otherOutcomes measure: Explorative endpoints, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06336304, orgStudyIdInfo id: NXTPMCF-01, briefTitle: NXT Post-Market Clinical Follow-up, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05, primaryCompletionDateStruct date: 2025-11, completionDateStruct date: 2025-12, studyFirstPostDateStruct date: 2024-03-28, lastUpdatePostDateStruct date: 2024-03-28, sponsorCollaboratorsModule leadSponsor name: Laborie Medical Technologies Inc., class: INDUSTRY, descriptionModule briefSummary: NXT Urodynamics System Post-Market Clinical Follow-up Clinical Investigation to Confirm Ongoing Safety and Performance in Urodynamic Patient Sub-Populations, conditionsModule conditions: Urinary Incontinence, conditions: Urinary Obstruction, conditions: Urinary Bladder, Overactive, conditions: Urinary Bladder, Neurogenic, conditions: Urinary Incontinence, Urge, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 180, type: ESTIMATED, armsInterventionsModule, outcomesModule primaryOutcomes measure: Assess NXT system performance, primaryOutcomes measure: Assess NXT system safety, secondaryOutcomes measure: Assess NXT system performance, eligibilityModule sex: ALL, stdAges: CHILD, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06336291, orgStudyIdInfo id: PH-L19TNFLOM-01/23, briefTitle: A Study With L19TNF in Combination With Lomustine in Patients With Glioblastoma at Progression or Recurrence, acronym: GLIOSTELLA, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-06, primaryCompletionDateStruct date: 2026-06, completionDateStruct date: 2026-06, studyFirstPostDateStruct date: 2024-03-28, lastUpdatePostDateStruct date: 2024-03-28, sponsorCollaboratorsModule leadSponsor name: Philogen S.p.A., class: INDUSTRY, descriptionModule briefSummary: The trial aims to collect safety, efficacy, exposure, dose- response, pharmacokinetic and pharmacodynamic information of the combination of L19TNF and lomustine at different dose levels in patients with Glioblastoma at progression or recurrence, conditionsModule conditions: Glioblastoma, designModule studyType: INTERVENTIONAL, phases: PHASE2, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 90, type: ESTIMATED, armsInterventionsModule interventions name: L19TNF, interventions name: L19TNF, interventions name: L19TNF, interventions name: Lomustine, interventions name: Lomustine, outcomesModule primaryOutcomes measure: Adverse Events, primaryOutcomes measure: Serious Adverse Events, primaryOutcomes measure: Unacceptable Toxicity, primaryOutcomes measure: DILI assessment, primaryOutcomes measure: Survival, secondaryOutcomes measure: Overall Survival, secondaryOutcomes measure: Progression Free Survival, secondaryOutcomes measure: Objective Response Rate, secondaryOutcomes measure: Disease Control Rate, secondaryOutcomes measure: Duration of Response, secondaryOutcomes measure: Time to reach maximum drug concentration [Tmax], secondaryOutcomes measure: Terminal half-life [t1/2], secondaryOutcomes measure: Area under the drug concentration-time curve, extrapolated to infinity [AUC], secondaryOutcomes measure: Maximum drug concentration [Cmax], secondaryOutcomes measure: Human anti-fusion protein antibodies (HAFA) levels against L19TNF, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06336278, orgStudyIdInfo id: 19/03/2024, briefTitle: Relationship Between Central Sensitization and Kinesiophobia in Knee Osteoarthritis, statusModule overallStatus: COMPLETED, startDateStruct date: 2022-10-01, primaryCompletionDateStruct date: 2023-10-01, completionDateStruct date: 2023-12-01, studyFirstPostDateStruct date: 2024-03-28, lastUpdatePostDateStruct date: 2024-04-22, sponsorCollaboratorsModule leadSponsor name: Selda Sarıkaya, class: OTHER, descriptionModule briefSummary: Objective: The knee joint is one of most common locations in OA. In recent years, it has been accepted that there are different pain phenotypes and patient subgroups in knee OA and that central sensitization (CS) mechanisms are at the forefront in some patients. It is also known that fear of movement, known as kinesiophobia, develops in patients with chronic pain. The aim of this study is to investigate CS and kinesiophobia in patients with knee OA, their relationships with each other, and their effects on pain intensity, functional status, pain catastrophizing and depression.Materials and Methods: Forty-two patients with knee OA and 42 healthy subjects participated in our study. Demographic data, body mass index, habits, comorbidities, medications of participants and disease duration and radiographic grade of knee OA patients were recorded. VAS was used to assess the severity of pain and WOMAC was used to assess pain and functional status in patients with OA. Algometer (pressure pain threshold measurement) and Central Sensitization Inventory were used to evaluate central sensitization in all participants. Pressure pain threshold (PPT) was measured at 3 different points: knee joint, cruris and forearm. The presence of kinesiophobia was assessed with the Tampa Scale af Kinesiophobia (TSK). Pain Catastrophizing Scale (PCS) and Beck Depression Inventory (BDI) were used to assess chronic pain related symptoms., conditionsModule conditions: Knee Osteoarthritis, conditions: Central Sensitisation, conditions: Kinesiophobia, designModule studyType: OBSERVATIONAL, designInfo observationalModel: CASE_CONTROL, timePerspective: CROSS_SECTIONAL, enrollmentInfo count: 84, type: ACTUAL, armsInterventionsModule interventions name: Pressure Algometer, outcomesModule primaryOutcomes measure: Pain Pressure Treshold, primaryOutcomes measure: Central Sensitization, primaryOutcomes measure: Kinesiophobia, secondaryOutcomes measure: Pain Catastrophizing, secondaryOutcomes measure: Depression, secondaryOutcomes measure: Visuel Analog Scala, secondaryOutcomes measure: Western Ontario and McMaster Universitesies Osteoarthritis Index, eligibilityModule sex: ALL, minimumAge: 45 Years, maximumAge: 75 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Zonguldak Bulent Ecevit Universitiy, city: Zonguldak, zip: 67100, country: Turkey, geoPoint lat: 41.45139, lon: 31.79305, hasResults: False
protocolSection identificationModule nctId: NCT06336265, orgStudyIdInfo id: Diaphragm ultrasound, briefTitle: Diaphragmatic Ultrasound to Predict the Therapeutic Effect of High-flow Nasal Cannula Oxygen Therapy, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-01, primaryCompletionDateStruct date: 2024-12-31, completionDateStruct date: 2024-12-31, studyFirstPostDateStruct date: 2024-03-28, lastUpdatePostDateStruct date: 2024-03-28, sponsorCollaboratorsModule leadSponsor name: Xingui Dai, class: OTHER, descriptionModule briefSummary: Follow-up was conducted for every patient requiring high-flow nasal cannula oxygen therapy in district 1 of the Intensive Care Department of Chenzhou NO.1 People's Hospital. Patients who met the inclusion criteria but did not meet the exclusion criteria were included for observation. Respiratory parameters, diaphragmatic activity, and variation rate of diaphragmatic thickness were recorded at the beginning of high-flow nasal cannula oxygen therapy, 1 hour after treatment, 3 hours after treatment, 6 hours after treatment, 9 hours after treatment, and 12 hours after treatment. Throughout the procedure, a panel of experts assessed whether the patient needed endotracheal intubation; If yes, the study was terminated; if no, high-flow nasal cannula oxygen therapy was continued, and observation and evaluation were continued until the end point of the study (12 hours after treatment). If patients or their family members do not want to continue to participate in the study during the study, they will be considered as withdrawal. If patients suffer from sudden malignant arrhythmia or cardiac arrest during the study, resulting in death or transfer to other hospitals or other departments during the study, patients will be excluded. Data from dropped and excluded patients were not included in the final statistical analysis. After the data of 269 patients were collected, the study was concluded, and the results and conclusions were derived by statistical analysis., conditionsModule conditions: Hypoxic Respiratory Failure, designModule studyType: OBSERVATIONAL, designInfo observationalModel: CASE_ONLY, timePerspective: PROSPECTIVE, enrollmentInfo count: 269, type: ESTIMATED, armsInterventionsModule interventions name: Diaphragm ultrasound, outcomesModule primaryOutcomes measure: Thickness and thickening fraction of Diaphragm, primaryOutcomes measure: Diaphragmatic excursion, primaryOutcomes measure: Respiratory rate, primaryOutcomes measure: Incidence of tracheal intubation, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 75 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False